Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Clinical trial NCT03829410 · COMPLETED
Trial details
- NCT number
- NCT03829410
- Sponsor
- Cardiff Oncology
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-24
- Primary completion
- 2024-01-29
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.